Literature DB >> 21617703

A member of the ETS family, EHF, and the ATPase RUVBL1 inhibit p53-mediated apoptosis.

Kenzui Taniue1, Takeaki Oda, Tomoatsu Hayashi, Masumi Okuno, Tetsu Akiyama.   

Abstract

Tumour cells are known to be dependent on, or 'addicted to', not only oncogenes, but also some non-oncogenes. However, the mechanisms by which tumour cells are addicted to these genes have not been fully explained. Here, we show that overexpression of a member of the ETS family, EHF, is required for the survival of colon tumour cells that contain wild-type p53. We found that EHF directly activates the transcription of RUVBL1, an ATPase associated with chromatin-remodelling complexes. RUVBL1 blocks p53-mediated apoptosis by repressing the expression of p53 and its target genes. Moreover, we found that RUVBL1 represses p53 transcription by binding to the p53 promoter, interfering with RNF20/hBRE1-mediated histone H2B monoubiquitination and promoting PAF1-mediated histone H3K9 trimethylation. These results indicate that EHF-mediated RUVBL1 expression allows colon tumour cells to avoid p53-mediated apoptosis. Thus, EHF and RUVBL1 might be promising molecular targets for the treatment of colon tumours.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617703      PMCID: PMC3128968          DOI: 10.1038/embor.2011.81

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  24 in total

Review 1.  The ETS-domain transcription factor family.

Authors:  A D Sharrocks
Journal:  Nat Rev Mol Cell Biol       Date:  2001-11       Impact factor: 94.444

2.  Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II.

Authors:  Rushad Pavri; Bing Zhu; Guohong Li; Patrick Trojer; Subhrangsu Mandal; Ali Shilatifard; Danny Reinberg
Journal:  Cell       Date:  2006-05-19       Impact factor: 41.582

3.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 5.  ETS transcription factors and their emerging roles in human cancer.

Authors:  Arun Seth; Dennis K Watson
Journal:  Eur J Cancer       Date:  2005-10-06       Impact factor: 9.162

6.  The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II.

Authors:  Armelle Yart; Matthias Gstaiger; Christiane Wirbelauer; Maria Pecnik; Dimitrios Anastasiou; Daniel Hess; Wilhelm Krek
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

7.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 8.  Gefitinib--a novel targeted approach to treating cancer.

Authors:  Roy S Herbst; Masahiro Fukuoka; José Baselga
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

9.  The adenomatous polyposis coli-associated exchange factors Asef and Asef2 are required for adenoma formation in Apc(Min/+)mice.

Authors:  Yoshihiro Kawasaki; Shinnosuke Tsuji; Ken Muroya; Shiori Furukawa; Yoko Shibata; Masumi Okuno; Susumu Ohwada; Tetsu Akiyama
Journal:  EMBO Rep       Date:  2009-11-06       Impact factor: 8.807

Review 10.  Tumour suppression by p53: a role for the DNA damage response?

Authors:  David W Meek
Journal:  Nat Rev Cancer       Date:  2009-09-04       Impact factor: 60.716

View more
  17 in total

1.  ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.

Authors:  Tiansuo Zhao; Wenna Jiang; Xiuchao Wang; Hongwei Wang; Chen Zheng; Yang Li; Yan Sun; Chongbiao Huang; Zhi-Bo Han; Shengyu Yang; Zhiliang Jia; Keping Xie; He Ren; Jihui Hao
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

2.  Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.

Authors:  Y Zhao; C Zhang; X Yue; X Li; J Liu; H Yu; V A Belyi; Q Yang; Z Feng; W Hu
Journal:  Cell Death Differ       Date:  2015-04-10       Impact factor: 15.828

3.  ASBEL-TCF3 complex is required for the tumorigenicity of colorectal cancer cells.

Authors:  Kenzui Taniue; Akiko Kurimoto; Yasuko Takeda; Takeshi Nagashima; Mariko Okada-Hatakeyama; Yuki Katou; Katsuhiko Shirahige; Tetsu Akiyama
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-21       Impact factor: 11.205

4.  Pontin, a novel interactor of mutant p53 that promotes mutant p53 gain of function.

Authors:  Yuhan Zhao; Xuetian Yue; Wenwei Hu
Journal:  Mol Cell Oncol       Date:  2015-07-29

5.  Ets homologous factor (EHF) has critical roles in epithelial dysfunction in airway disease.

Authors:  Sara L Fossum; Michael J Mutolo; Antonio Tugores; Sujana Ghosh; Scott H Randell; Lisa C Jones; Shih-Hsing Leir; Ann Harris
Journal:  J Biol Chem       Date:  2017-05-01       Impact factor: 5.157

6.  Downregulation of RUVBL1 inhibits proliferation of lung adenocarcinoma cells by G1/S phase cell cycle arrest via multiple mechanisms.

Authors:  Xiao-Shuai Yuan; Zhi-Tian Wang; Ye-Ji Hu; Fei-Chao Bao; Ping Yuan; Chong Zhang; Jin-Lin Cao; Wang Lv; Jian Hu
Journal:  Tumour Biol       Date:  2016-10-10

7.  UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells.

Authors:  Kenzui Taniue; Tomoatsu Hayashi; Yuki Kamoshida; Akiko Kurimoto; Yasuko Takeda; Lumi Negishi; Kei Iwasaki; Yoshifumi Kawamura; Naoki Goshima; Tetsu Akiyama
Journal:  Oncogene       Date:  2019-10-03       Impact factor: 9.867

8.  Expression of ESE-3 isoforms in immunogenic and tolerogenic human monocyte-derived dendritic cells.

Authors:  Florian Sprater; Arnt-Ove Hovden; Silke Appel
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

9.  Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.

Authors:  Brian J O'Roak; Laura Vives; Wenqing Fu; Jarrett D Egertson; Ian B Stanaway; Ian G Phelps; Gemma Carvill; Akash Kumar; Choli Lee; Katy Ankenman; Jeff Munson; Joseph B Hiatt; Emily H Turner; Roie Levy; Diana R O'Day; Niklas Krumm; Bradley P Coe; Beth K Martin; Elhanan Borenstein; Deborah A Nickerson; Heather C Mefford; Dan Doherty; Joshua M Akey; Raphael Bernier; Evan E Eichler; Jay Shendure
Journal:  Science       Date:  2012-11-15       Impact factor: 47.728

10.  The spliceosome-activating complex: molecular mechanisms underlying the function of a pleiotropic regulator.

Authors:  Csaba Koncz; Femke Dejong; Nicolas Villacorta; Dóra Szakonyi; Zsuzsa Koncz
Journal:  Front Plant Sci       Date:  2012-01-26       Impact factor: 5.753

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.